DOCETAXEL AND IFOSFAMIDE AS SECOND LINE TREATMENT FOR PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CANCER AFTER FAILURE OF PLATINUM CHEMOTHERAPY: A PHASE 2 STUDY

Abstract

The combination of docetaxel and ifosfamide is active in previously treated patients with urothelial cancer, although it appears to be a reasonable treatment option only in those with lymph node dominant recurrence. The mild toxicity underlines the usefulness of the regimen in this setting. Further investigation of the combination in previously untreated patients seems warranted.